Skip to Content
Merck

Skip To

SML2183

LY2955303

≥98% (HPLC)

Synonym(s):

4-[5-[3,5-bis(1,1-Dimethylethyl)phenyl]-1-[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]-1H-pyrazol-3-yl]-benzoic acid, LY 2955303

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice
25 mg
Please contact Customer Service for Availability
PLN 1,480.00

About This Item

Empirical Formula (Hill Notation):
C36H42N4O3
CAS Number:
Molecular Weight:
578.74
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder

PLN 1,480.00


Please contact Customer Service for Availability

Request a Bulk Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

CC(C)(C)C1=CC(C2=CC(C3=CC=C(C(O)=O)C=C3)=NN2C4=CC=C(C=C4)C(N5CCN(CC5)C)=O)=CC(C(C)(C)C)=C1

InChI key

YVXYHNKIOFSFMZ-UHFFFAOYSA-N

Biochem/physiol Actions

LY2955303 is a potent and selective RARγ antagonist (Ki = 1.09 nM/RARγ, >1.70 μM/RARα, >2.98 μM/RARβ) that effectively inhibits RARγ-, but not RARα- or RARβ-, dependent reporter activity upon 15 nM all-trans retinoic acid stimulation in respective HEK293 transfectants (KB = 7.11 nM/RARγ, 1.51 μM/RARβ, 4.44 μM/RARα; 10 nM ATRA for RARβ transfectant). LY2955303 exhibits therapeutic efficacy in a rat model of osteoarthritis-like joint pain (ED50 = 0.72 mg/kg; single p.o. dosage 9 days post OA pain induction by MIA intra-articular injection) with good pharmacokinetic properties, aqueous solubility (>1.0 mg/mL in simulated intestinal fluid), oral availability (F = 26%; 10 mg/kg p.o. over 2 mg/kg i.v.), and no RARα antagonism-associated adverse effects (no testicular degeneration up to 10 mg/kg) seen with BMS-189453 treatment or in RARα-knockout mice.
Potent and selective retinoic acid receptor gamma (RARγ) antagonist with oral availability and in vivo efficacy in a rat model of osteoarthritis-like joint pain.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
SML2892SML1145SML2384
assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

form

powder

form

powder

form

powder

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: 20 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear

color

white to beige

color

white to beige

color

white to beige

color

white to beige


Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Norman E Hughes et al.
Bioorganic & medicinal chemistry letters, 26(14), 3274-3277 (2016-06-05)
A series of triaryl pyrazoles were identified as potent pan antagonists for the retinoic acid receptors (RARs) α, β and γ. X-ray crystallography and structure-based drug design were used to improve selectivity for RARγ by targeting residue differences in the



Global Trade Item Number

SKUGTIN
SML2183-5MG04061835503391
SML2183-25MG04061835503407

Questions

Reviews

No rating value

Active Filters